Real-World Treatment Patterns and Persistence of Omidenepag Isopropyl in Korean Patients with Normal-Tension Glaucoma
- 1Department of Ophthalmology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul 05030, Republic of Korea
Abstract
Background/Objectives: Prostaglandin analogues may cause prostaglandin-associated periorbitopathy (PAP). Omidenepag isopropyl (OMDI), a selective EP2 receptor agonist, may provide an alternative, but real-world data in normal-tension glaucoma (NTG) are limited. We evaluated treatment patterns, persistence, and intraocular pressure (IOP) outcomes of OMDI in Korean patients with NTG. Methods: This retrospective study included 403 eyes of 218 patients with NTG who initiated OMDI and were followed for up to 12 months. Patients received monotherapy, adjunctive therapy, or switching therapy. IOP was analyzed using a three-level linear mixed-effects model, and persistence was assessed using Kaplan–Meier analysis. Results: OMDI was prescribed as monotherapy in 88 patients (40.4%), adjunctive therapy in 25 (11.5%), and switching therapy in 105 (48.2%). Among switchers, PAP was the most common reason (68.6%). IOP decreased significantly in all groups (all p < 0.001), with model-estimated 12-month changes of −4.08, −3.37, and −1.40 mmHg, respectively. Twelve-month persistence was 79.8%. OMDI was discontinued in 44 patients (20.2%), most commonly because of visual disturbance or decreased vision (38.6%). Conclusions: OMDI provided sustained IOP reduction and 79.8% 12-month persistence in Korean patients with NTG and was frequently selected as an alternative to prostaglandin analogues in patients with PAP.
Related
- A Team‐Based Patient Engagement Approach to Selexipag Initiation and Maintenance in Pulmonary Arterial Hypertension (TEAM PAH): Real‐World Dosing Patterns and Persistence Among Patients With and Without a History of Methamphetamine Use
- Treatment patterns and determinants of persistence with advanced therapies in adults with newly diagnosed Crohn's disease: an interim analysis of an inception cohort registry study (iCREST-CD).
- Multidimensional patterns of malocclusion in treatment-seeking Turkish orthodontic patients : A retrospective cross-sectional study
- Treatment patterns and prognostic factors of radiation-associated esophageal fistula in patients with esophageal squamous cell carcinoma: a retrospective cohort study
- Cardiovascular risk profile and treatment patterns in patients with type 2 diabetes in specialized cardiology outpatient care in Colombia : A retrospective cross-sectional study
BibTeX
@article{kim2026realworld,
title = {{Real-World Treatment Patterns and Persistence of Omidenepag Isopropyl in Korean Patients with Normal-Tension Glaucoma}},
author = {Na Hee Kim and Youn Hye Jo},
journal = {Journal of Clinical Medicine},
year = {2026},
month = oct,
doi = {10.3390/jcm15208200},
url = {https://www.mdpi.com/2077-0383/15/20/8200},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Real-World Treatment Patterns and Persistence of Omidenepag Isopropyl in Korean Patients with Normal-Tension Glaucoma
AU - Na Hee Kim
AU - Youn Hye Jo
PY - 2026
DA - 2026/10/21
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15208200
UR - https://www.mdpi.com/2077-0383/15/20/8200
AB - Background/Objectives: Prostaglandin analogues may cause prostaglandin-associated periorbitopathy (PAP). Omidenepag isopropyl (OMDI), a selective EP2 receptor agonist, may provide an alternative, but real-world data in normal-tension glaucoma (NTG) are limited. We evaluated treatment patterns, persistence, and intraocular pressure (IOP) outcomes of OMDI in Korean patients with NTG. Methods: This retrospective study included 403 eyes of 218 patients with NTG who initiated OMDI and were followed for up to 12 months. Patients received monotherapy, adjunctive therapy, or switching therapy. IOP was analyzed using a three-level linear mixed-effects model, and persistence was assessed using Kaplan–Meier analysis. Results: OMDI was prescribed as monotherapy in 88 patients (40.4%), adjunctive therapy in 25 (11.5%), and switching therapy in 105 (48.2%). Among switchers, PAP was the most common reason (68.6%). IOP decreased significantly in all groups (all p < 0.001), with model-estimated 12-month changes of −4.08, −3.37, and −1.40 mmHg, respectively. Twelve-month persistence was 79.8%. OMDI was discontinued in 44 patients (20.2%), most commonly because of visual disturbance or decreased vision (38.6%). Conclusions: OMDI provided sustained IOP reduction and 79.8% 12-month persistence in Korean patients with NTG and was frequently selected as an alternative to prostaglandin analogues in patients with PAP.
SN - 2077-0383
ER -